Skip to main content
. Author manuscript; available in PMC: 2023 Jun 16.
Published in final edited form as: Cancer Res. 2022 Dec 16;82(24):4624–4640. doi: 10.1158/0008-5472.CAN-22-0736

Figure 5. STAT2, but not STAT1, mediates the type I interferon signaling that is activated upon EZH2 inhibition.

Figure 5.

(A-B) Western blot with specified antibodies in MCF-7 cells stably expressing two EZH2-specific shRNAs (shEZH2–4 and -A) or treated with 5 μM EZH2 inhibitors (GSK126 and EPZ-6438) for 7 days (A) or in the presence of 5 μM GSK126, either alone (–) or with (+) 2 μg/mL IFNβ-specific neutralizing antibody (α-IFNβ), for 7 days (B) (C-H) Immunoblotting analysis (C-D), cell proliferation (E and G) and expression of exemplary genes (F and H) in MCF-7 cells upon knockdown of STAT1 (shSTAT1, C and E-F) or STAT2 (shSTAT2–1 and −2, D and G-H) in the presence of 5 μM GSK126 for indicated period of time (E and G) or up to 7 days (F and H).